WallStreetZenWallStreetZen

NASDAQ: PHAT
Phathom Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for PHAT

Based on 2 analysts offering 12 month price targets for Phathom Pharmaceuticals Inc.
Min Forecast
$10.00-2.82%
Avg Forecast
$18.00+74.93%
Max Forecast
$26.00+152.67%

Should I buy or sell PHAT stock?

Based on 2 analysts offering ratings for Phathom Pharmaceuticals Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PHAT stock forecasts and price targets.

PHAT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-23
lockedlocked$00.00+00.00%2023-11-03

1 of 1

Forecast return on equity

Is PHAT forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is PHAT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

PHAT revenue forecast

What is PHAT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$33.1M
Avg 2 year Forecast
$115.6M
Avg 3 year Forecast
$254.8M

PHAT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHAT$10.29$18.00+74.93%Buy
ALT$11.05$16.00+44.80%Buy
ADPT$3.99$7.25+81.70%Buy
URGN$18.42$43.00+133.44%Buy
MLYS$14.99N/AN/A

Phathom Pharmaceuticals Stock Forecast FAQ

Is Phathom Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: PHAT) stock is to Buy PHAT stock.

Out of 2 analysts, 0 (0%) are recommending PHAT as a Strong Buy, 1 (50%) are recommending PHAT as a Buy, 1 (50%) are recommending PHAT as a Hold, 0 (0%) are recommending PHAT as a Sell, and 0 (0%) are recommending PHAT as a Strong Sell.

If you're new to stock investing, here's how to buy Phathom Pharmaceuticals stock.

What is PHAT's revenue growth forecast for 2024-2026?

(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.84%.

Phathom Pharmaceuticals's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast PHAT's revenue for 2024 to be $1,894,485,854, with the lowest PHAT revenue forecast at $1,178,829,366, and the highest PHAT revenue forecast at $2,610,199,594. On average, 2 Wall Street analysts forecast PHAT's revenue for 2025 to be $6,618,333,944, with the lowest PHAT revenue forecast at $6,141,477,713, and the highest PHAT revenue forecast at $7,095,190,175.

In 2026, PHAT is forecast to generate $14,590,518,205 in revenue, with the lowest revenue forecast at $13,055,291,908 and the highest revenue forecast at $16,125,801,754.

What is PHAT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PHAT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is PHAT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year PHAT price target, the average PHAT price target is $18.00, with the highest PHAT stock price forecast at $26.00 and the lowest PHAT stock price forecast at $10.00.

On average, Wall Street analysts predict that Phathom Pharmaceuticals's share price could reach $18.00 by Feb 23, 2025. The average Phathom Pharmaceuticals stock price prediction forecasts a potential upside of 74.93% from the current PHAT share price of $10.29.

What is PHAT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PHAT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.